Gene · 64848
Papers1,809
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,809
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| m6A RNA Methylation and Implications for Hepatic Lipid Metabolism. | DNA Cell Biol | 2024 | 38635960 | PubTator, text mining | PubMed |
| Interferon-α stimulates DExH-box helicase 58 to prevent hepatocyte ferroptosis. | Mil Med Res | 2024 | 38622688 | PubTator, text mining | PubMed |
| NME6 as a potential biomarker and therapeutic target involved in immune infiltration for lung adenocarcinoma. | Technol Health Care | 2024 | 38517815 | PubTator, text mining | PubMed |
| Construction and validation of m6A-related diagnostic model for psoriasis. | PeerJ | 2024 | 38436011 | PubTator, text mining | PubMed |
| METTL3 knockdown suppresses RA-FLS activation through m6A-YTHDC2-mediated regulation of AMIGO2. | Biochim Biophys Acta Mol Basis Dis | 2024 | 38432455 | PubTator, text mining | PubMed |
| CircYthdc2 generates polypeptides through two translation strategies to facilitate virus escape. | Cell Mol Life Sci | 2024 | 38361078 | PubTator, text mining | PubMed |
| METTL16 inhibits papillary thyroid cancer tumorigenicity through m6A/YTHDC2/SCD1-regulated lipid metabolism. | Cell Mol Life Sci | 2024 | 38334797 | PubTator, text mining | PubMed |
| Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours. | Clin Transl Med | 2024 | 38303608 | PubTator, text mining | PubMed |
| Analysis of m6A regulators related immune characteristics in ankylosing spondylitis by integrated bioinformatics and computational strategies. | Sci Rep | 2024 | 38302672 | PubTator, text mining | PubMed |
| Experimental prognostic model integrating N6-methyladenosine-related programmed cell death genes in colorectal cancer. | iScience | 2024 | 38299031 | PubTator, text mining | PubMed |
| Modification patterns and metabolic characteristics of m6A regulators in digestive tract tumors. | Heliyon | 2024 | 38298699 | PubTator, text mining | PubMed |
| Effects of N6-methyladenosine modification on metabolic reprogramming in digestive tract tumors. | Heliyon | 2024 | 38293446 | PubTator, text mining | PubMed |
| The m6A methyltransferase METTL3 drives thyroid cancer progression and lymph node metastasis by targeting LINC00894. | Cancer Cell Int | 2024 | 38291427 | PubTator, text mining | PubMed |
| A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia. | Exp Hematol Oncol | 2024 | 38268050 | PubTator, text mining | PubMed |
| Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma. | BMC Cancer | 2024 | 38262966 | PubTator, text mining | PubMed |
| BMP9-ID1 Pathway Attenuates N6-Methyladenosine Levels of CyclinD1 to Promote Cell Proliferation in Hepatocellular Carcinoma. | Int J Mol Sci | 2024 | 38256056 | PubTator, text mining | PubMed |
| LOX-1 acts as an N6-methyladenosine-regulated receptor for Helicobacter pylori by binding to the bacterial catalase. | Nat Commun | 2024 | 38253620 | PubTator, text mining | PubMed |
| The inhibition of YTHDF3/m6A/LRP6 reprograms fatty acid metabolism and suppresses lymph node metastasis in cervical cancer. | Int J Biol Sci | 2024 | 38250152 | PubTator, text mining | PubMed |
| Development of an m6A-Related lncRNAs Signature Predicts Tumor Stemness and Prognosis for Low-Grade Glioma Patients. | Stem Cells Int | 2024 | 38229597 | PubTator, text mining | PubMed |
| The pyroptosis-related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma. | Open Med (Wars) | 2024 | 38221934 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64848/papers?page=7